The product has been added to the cart.
By using our website, you agree to our use of cookies. find out more.
-
Products
Pharmacology
Type
- News
- Custom services
- Ordering
- About Us
- Technical support
- Resources
-
Products
Pharmacology
Type
- News
- Custom services
- Ordering
- About Us
- Technical support
- Resources
EGFRvIII peptide
Cat. No. EP-040
Structure:
H-Leu-Glu-Glu-Lys-Lys-Gly-Asn-Tyr-Val-OH
Other Names:
PEGFRvIII, Epidermal growth factor receptor variant III peptide
Activity:
EGFRvIII derived epitope
EGFRvIII peptide is a peptide derived from the fusion junction of epidermal growth factor receptor variant III (EGFRvIII), a variant of EGFR with amino acids 6–273 deleted. This spontaneously occurring alteration is found in a high percentage of primary human brain, breast, lung and ovarian tumours making EGFRvIII an ideal target of immunotherapy in EGFRvIII-expressing tumours. EGFRvIII peptide was identified from a number of candidates as the most immunogenic epitope for major histocompatibility complex I (MHC I) binding to induce tumour specific immune responses. In a glioblastoma mouse brain tumour model EGFRvIII peptide co-administered with the toll-like receptor 5 (TLR5) adjuvant Flagellin B induces an increase in CD8 + T cells and a decrease in Treg cells, inducing tumour apoptosis, inhibiting tumour growth and increasing survival.
Moscatello et al (1997) A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res. 57(8) 1419 PMID: 9108438
Wu et al (2006) Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol. 76(1) 23 PMID: 16155724
Choi et al (2022) Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model. BMC Cancer 22(1) 986 PMID: 36109710
Related areas
All epitopes >
All cancer research categories >
All immunology research categories >
Technical Data
| Structure | H-Leu-Glu-Glu-Lys-Lys-Gly-Asn-Tyr-Val-OH |
| Molecular Weight | 1078.57 |
| Formula | C48H78N12O16 |
| Sequence | LEEKKGNYV |
| Modifications | None |
Solubility and Storage
| Solubility | Soluble in water |
| Appearance | Freeze dried solid |
| Storage | Store dry, frozen and in the dark |
Batch Specific Data
| Purity | >95% by hplc |
Contact Information
To place an order, or for customer services, order processing or technical support please contact us on:
UK, Europe and RoW
Tel: (+44) 01392 422205
Fax: (+44) 01392 279510
info@iscabiochemicals.com
USA and Canada
Tel: 610-994-1134
Toll Free: 855-FOCUS21 (855-362-8721)
Fax: 610-465-9100
France
CliniSciences
Tel : +33 9 77 40 09 09
Fax : +33 9 77 40 10 11
Orders and customer support : info@clinisciences.com
Germany, Switzerland, Austria
BIOZOL Diagnostics
Tel: +49 (089) 3799 666-6
Fax: +49 (089) 3799 666-99
Orders, Technical and Customer support: info@biozol.de
Italy
Labospace
Tel: +39 02 35980841
Fax +39 02 359808004
Orders: info@labospace.com
Spain and Portugal
Abyntek Biopharma
Tel: +34 94 404 80 80
Fax: +34 94 404 80 81
Orders: info@abyntek.com
BIOHUB INTERNATIONAL
上海起发实验试剂有限公司
Tel: +86-15921799099
Tel: +86-021-50724187
Fax: +86-021-50724961
Orders: sale3@78bio.com
India
BTL Biotechno Labs Pvt Ltd
Tel: +91-8860924629
07291852429
Orders, Technical and Customer support: info@biotechnolabs.com
Japan
Namiki Shoji Co.
Tel：+81-050-5527-9850
Fax：+81-3-3352-2196
email: globalbusiness1@namiki-s.co.jp
Recent citations
A new publication from the University of Ljubljana uses MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2, the FRET substrate for the severe acute respiratory syndrome coronavirus main protease (SARS-CoV Mpro), to determine the inhibitory potential of plant polyphenols
Learn moreContact us
Isca Biochemicals
26 Hanover Road
Exeter
EX1 2TL
(+44) 01392 422205
info@iscabiochemicals.com
© 2025 Isca Biochemicals. All rights reserved.
Designed and developed by tocostudio